Managing a malignant renal tumor requires, first of all, a reflection on the necessity of its treatment. It must consider the renal function, altered at the time of diagnosis in 50% of cases. The treatment method chosen depends on many factors, in particular, the predicted residual renal function, the risk of chronic kidney disease, the need for temporary or long-term dialysis, and overall long-term survival. Other factors include the size, position, and number of tumors and a hereditary tumor background. When a renal-sparing management alternative is available, total nephrectomy should no longer be performed in patients with small malignant renal masses (cT1a). This may consist of surgery (partial nephrectomy or lumpectomy), percutaneous thermo-ablation (by radiofrequency, microwave, or cryotherapy). In patients with limited life expectancy, imaging-based surveillance may be proposed to suggest treatment in case of local progression. Good coordination between urologist, radiologist, nephrologist, and sometimes radiotherapist should allow optimal management of patients with a malignant renal tumor with or without underlying renal failure.
Keywords: Ablation percutanée; Cancer rénal; Nephronic sparing therapy; Néphrectomie partielle; Partial nephrectomy; Percutaneous tumor ablation; Radiothérapie stéréotaxique; Renal cancer; Stereotactic radiotherapy; Traitement avec épargne néphronique.
Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.